Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
Brianna L Combs, Arthur G Cox Department of Pharmaceutical Sciences, Sullivan University College of Pharmacy, Louisville, KY, USA Abstract: Parkinson’s disease (PD) has a prevalence of nearly 1 million people in the USA, with increasing incidence in the elderly population. Generally, the...
Guardado en:
Autores principales: | Combs BL, Cox AG |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e813b878a83e45f79426936c56c945e5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
High frequency of psychosis in late-stage Parkinsońs disease
por: Inês Chendo, et al.
Publicado: (2021) -
Psychosis in parkinsonism: an unorthodox approach
por: Onofrj M, et al.
Publicado: (2017) -
Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
por: Zhang H, et al.
Publicado: (2019) -
The role of deep brain stimulation in Parkinson’s disease: an overview and update on new developments
por: Fang JY, et al.
Publicado: (2017) -
Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis
por: Michael S. Kraus, et al.
Publicado: (2022)